vs
Side-by-side financial comparison of Frontdoor, Inc. (FTDR) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Frontdoor, Inc. is the larger business by last-quarter revenue ($451.0M vs $281.3M, roughly 1.6× Guardant Health, Inc.). Frontdoor, Inc. runs the higher net margin — 9.1% vs -45.7%, a 54.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 5.9%). Frontdoor, Inc. produced more free cash flow last quarter ($114.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -8.8%).
Frontdoor, Inc. operates a leading U.S.-focused home services and protection platform. It offers customizable home warranty plans covering repairs and replacements for household appliances, HVAC, plumbing, and electrical systems, plus on-demand access to a network of pre-vetted local service professionals for residential maintenance and repairs.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
FTDR vs GH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $451.0M | $281.3M |
| Net Profit | $41.0M | $-128.5M |
| Gross Margin | 55.0% | 64.6% |
| Operating Margin | — | -43.0% |
| Net Margin | 9.1% | -45.7% |
| Revenue YoY | 5.9% | 39.4% |
| Net Profit YoY | 10.8% | -15.8% |
| EPS (diluted) | $0.57 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $451.0M | — | ||
| Q4 25 | $432.0M | $281.3M | ||
| Q3 25 | $618.0M | $265.2M | ||
| Q2 25 | $617.0M | $232.1M | ||
| Q1 25 | $426.0M | $203.5M | ||
| Q4 24 | $383.0M | $201.8M | ||
| Q3 24 | $540.0M | $191.5M | ||
| Q2 24 | $542.0M | $177.2M |
| Q1 26 | $41.0M | — | ||
| Q4 25 | $1.0M | $-128.5M | ||
| Q3 25 | $106.0M | $-92.7M | ||
| Q2 25 | $111.0M | $-99.9M | ||
| Q1 25 | $37.0M | $-95.2M | ||
| Q4 24 | $9.0M | $-111.0M | ||
| Q3 24 | $100.0M | $-107.8M | ||
| Q2 24 | $92.0M | $-102.6M |
| Q1 26 | 55.0% | — | ||
| Q4 25 | 49.3% | 64.6% | ||
| Q3 25 | 57.1% | 64.7% | ||
| Q2 25 | 57.7% | 65.0% | ||
| Q1 25 | 55.2% | 63.3% | ||
| Q4 24 | 48.0% | 61.6% | ||
| Q3 24 | 56.7% | 61.1% | ||
| Q2 24 | 56.5% | 59.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | -43.0% | ||
| Q3 25 | 23.0% | -37.3% | ||
| Q2 25 | 23.7% | -45.9% | ||
| Q1 25 | 11.3% | -54.6% | ||
| Q4 24 | 1.6% | -62.4% | ||
| Q3 24 | 24.8% | -61.3% | ||
| Q2 24 | 22.9% | -56.8% |
| Q1 26 | 9.1% | — | ||
| Q4 25 | 0.2% | -45.7% | ||
| Q3 25 | 17.2% | -35.0% | ||
| Q2 25 | 18.0% | -43.0% | ||
| Q1 25 | 8.7% | -46.8% | ||
| Q4 24 | 2.3% | -55.0% | ||
| Q3 24 | 18.5% | -56.3% | ||
| Q2 24 | 17.0% | -57.9% |
| Q1 26 | $0.57 | — | ||
| Q4 25 | $0.03 | $-1.01 | ||
| Q3 25 | $1.42 | $-0.74 | ||
| Q2 25 | $1.48 | $-0.80 | ||
| Q1 25 | $0.49 | $-0.77 | ||
| Q4 24 | $0.10 | $-0.90 | ||
| Q3 24 | $1.30 | $-0.88 | ||
| Q2 24 | $1.18 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $603.0M | $378.2M |
| Total DebtLower is stronger | $1.2B | $1.5B |
| Stockholders' EquityBook value | $230.0M | $-99.3M |
| Total Assets | $2.2B | $2.0B |
| Debt / EquityLower = less leverage | 5.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $603.0M | — | ||
| Q4 25 | $566.0M | $378.2M | ||
| Q3 25 | $563.0M | $580.0M | ||
| Q2 25 | $562.0M | $629.1M | ||
| Q1 25 | $506.0M | $698.6M | ||
| Q4 24 | $436.0M | $525.5M | ||
| Q3 24 | $375.0M | $585.0M | ||
| Q2 24 | $419.0M | $933.7M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $565.0M | — | ||
| Q2 24 | $569.0M | — |
| Q1 26 | $230.0M | — | ||
| Q4 25 | $242.0M | $-99.3M | ||
| Q3 25 | $316.0M | $-354.5M | ||
| Q2 25 | $254.0M | $-305.5M | ||
| Q1 25 | $198.0M | $-250.8M | ||
| Q4 24 | $239.0M | $-139.6M | ||
| Q3 24 | $261.0M | $-60.1M | ||
| Q2 24 | $214.0M | $-1.6M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.1B | $2.0B | ||
| Q3 25 | $2.2B | $1.3B | ||
| Q2 25 | $2.2B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B |
| Q1 26 | 5.07× | — | ||
| Q4 25 | 4.73× | — | ||
| Q3 25 | 3.64× | — | ||
| Q2 25 | 4.56× | — | ||
| Q1 25 | 5.88× | — | ||
| Q4 24 | 4.90× | — | ||
| Q3 24 | 2.16× | — | ||
| Q2 24 | 2.66× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-26.4M |
| Free Cash FlowOCF − Capex | $114.0M | $-54.2M |
| FCF MarginFCF / Revenue | 25.3% | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $387.0M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $101.0M | $-26.4M | ||
| Q3 25 | $64.0M | $-35.4M | ||
| Q2 25 | $127.0M | $-60.3M | ||
| Q1 25 | $124.0M | $-62.7M | ||
| Q4 24 | $58.0M | $-64.5M | ||
| Q3 24 | $25.0M | $-51.1M | ||
| Q2 24 | $103.0M | $-94.0M |
| Q1 26 | $114.0M | — | ||
| Q4 25 | $95.0M | $-54.2M | ||
| Q3 25 | $58.0M | $-45.8M | ||
| Q2 25 | $120.0M | $-65.9M | ||
| Q1 25 | $117.0M | $-67.1M | ||
| Q4 24 | $50.0M | $-83.4M | ||
| Q3 24 | $16.0M | $-55.3M | ||
| Q2 24 | $91.0M | $-99.1M |
| Q1 26 | 25.3% | — | ||
| Q4 25 | 22.0% | -19.3% | ||
| Q3 25 | 9.4% | -17.3% | ||
| Q2 25 | 19.4% | -28.4% | ||
| Q1 25 | 27.5% | -33.0% | ||
| Q4 24 | 13.1% | -41.3% | ||
| Q3 24 | 3.0% | -28.9% | ||
| Q2 24 | 16.8% | -55.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 9.9% | ||
| Q3 25 | 1.0% | 3.9% | ||
| Q2 25 | 1.1% | 2.4% | ||
| Q1 25 | 1.6% | 2.2% | ||
| Q4 24 | 2.1% | 9.4% | ||
| Q3 24 | 1.7% | 2.2% | ||
| Q2 24 | 2.2% | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | 101.00× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 3.35× | — | ||
| Q4 24 | 6.44× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 1.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FTDR
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
